<DOC>
	<DOCNO>NCT02185261</DOCNO>
	<brief_summary>This study aim evaluate efficacy interferon α among patient undergone unmanipulated blood marrow transplantation follow day 60 post-transplantation minimal residual disease positive transplantation . Hematopoietic stem cell transplantation ( HSCT ) effective treatment option acute leukemia many hematological malignancy . However , post-transplant relapse occur patient , prognosis patient usually poor.The persistence recurrence minimal residual disease ( MRD ) post-transplant period independent risk factor relapse . Therefore , MRD monitoring use screen patient high risk relapse provide timely intervention prevent post-transplant relapse.Interferon α-2b exerts relatively strong immunomodulatory effect . It kill acute leukemia ( AL ) cell regulate T-cell and/or natural killer cell functions.Consequently , interferon α-2b may potential therapeutic value AL patient MRD-positive transplantation . The study hypothesis : Prevention relapse use interferon α-2b follow hematopoietic stem cell transplantation patient standard risk acute leukemia reduce relapse rate .</brief_summary>
	<brief_title>Interferon α Therapy Minimal Residual Disease</brief_title>
	<detailed_description>Standard risk acute leukemia patient ( except ( 9 ; 22 ) ( q34 ; q11 ) , ( 15 ; 17 ) , inv ( 16 ) ( p13q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) , ( 8 ; 21 ) ( q22 ; q22 ) cytogenetic abnormality . ) undergone unmanipulated blood marrow transplantation follow day 60 post-transplantation minimal residual disease positive hematopoietic stem cell transplantation receive interferon α-2b . The end point safety immunologic response . Following time 12 month . Primary Outcome Measures : *The feasibility efficacy administer subcutaneous interferon α-2b patient population . [ Time Frame : 1 year ] Secondary Outcome Measures : *The immunologic impact clinical outcome subcutaneous interferon α-2b patient unmanipulated blood marrow transplantation [ Time Frame : 1 year ] Estimated Enrollment:81 Study Start Date : Jun 2014 Estimated Study Completion Date : Jun 2016 Intervention Details Description : *Drug : Interferon α-2b ( subcutaneously dosages 3 million unit 2-3 time per week ) 6 month absence disease progression unacceptable toxicity . Acute leukemia patient MRD positive day 60 post-transplantation receive interferon α-2b ( subcutaneously dosages 3 million unit 2-3 time per week ) . Interferon α-2b continue 6 month absence disease progression unacceptable toxicity . Participants see periodically receive interferon α-2b . Physical exams blood test perform weekly first two week every week completion 6 month therapy . Eligibility Ages Eligible Study : 1-60 Years Genders Eligible Study : Both Accepts Healthy Volunteers : No Criteria The trial terminate follow situation 1 . Severe toxicity occurrence 2 . Cumulative incidence relapse increase ) ( ≥ 30 % ) 3 . Cumulative incidence mortality increase ( ≥ 30 % ) 4 . Cumulative incidence severe graft-versus-host disease increase ( ≥ 30 % ) 5 . Although large enough sample enrol , reach statistical significance</detailed_description>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients standardrisk acute myeloid leukemia ( CR1 CR2 ) minimal residual disease positive hematopoietic stem cell transplantation Patients ( 9 ; 22 ) ( q34 ; q11 ) , ( 15 ; 17 ) , inv ( 16 ) ( p13q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) , ( 8 ; 21 ) ( q22 ; q22 ) cytogenetic abnormality ; active graftversushost disease ; active infection ; organ failure ; exposure donor lymphocyte infusion prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>Acute leukemia</keyword>
	<keyword>Interferon Alfa-2b</keyword>
</DOC>